Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00313677 · ClinicalTrials.gov registry record

Clinical Trial Readiness for the Dystroglycanopathies

A clinical trial of Muscular Dystrophy, sponsored by Katherine Mathews.

Recruiting
Registry status
190
Enrollment target
1
Study location

NCT00313677: Recruiting study of Muscular Dystrophy, sponsored by Katherine Mathews.

NCT00313677 is a study of Muscular Dystrophy that is actively recruiting participants, run by Katherine Mathews. The registered enrollment target is 190 participants, below the 863-participant average among 11 other Muscular Dystrophy trials with a reported enrollment target (78% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00313677, a study of Muscular Dystrophy, is actively recruiting participants, sponsored by Katherine Mathews.

RECRUITING
Registry status
190 participants
Enrollment target
1
Study location

Study Summary

The purpose of the study is to describe the early signs and symptoms of the dystroglycanopathies, and to gather information that will be required for future clinical trials.

Primary Outcome

time to walk 10 meters without assistive device

Conditions Studied

Study Locations (1)

Iowa

  • University of Iowa, 200 Hawkins Drive - Iowa City

Trial Details

FieldValue
Enrollment Target 190 participants
Start Date 2006-04
Est. Completion 2030-07
Katherine Mathews

1 total trials

What NCT00313677 shows while recruiting

NCT00313677 is an observational study that tracks outcomes without assigning an intervention. The registered 190 participants enrollment target is mid-sized for trials with a published cap, below the 863-participant average among 11 other Muscular Dystrophy trials with a reported enrollment target (78% lower).

The record links to 1 condition, with Muscular Dystrophy appearing as the primary indexed condition, and to 0 interventions.

NCT00313677 reports a single indexed study location in Iowa.

Frequently Asked Questions

What is clinical trial NCT00313677 about?

NCT00313677 is a clinical study titled "Clinical Trial Readiness for the Dystroglycanopathies". The purpose of the study is to describe the early signs and symptoms of the dystroglycanopathies, and to gather information that will be required for future clinical trials.

What is the current status of trial NCT00313677?

This trial is currently recruiting. The enrollment target is 190 participants. The study started on 2006-04. Estimated completion is 2030-07.

What conditions does trial NCT00313677 study?

This clinical trial studies the following conditions: Muscular Dystrophy.

Who is sponsoring clinical trial NCT00313677?

This trial is sponsored by Katherine Mathews, which has 1 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00313677 being conducted?

This trial has 1 study location across Iowa. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Muscular Dystrophy

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT00313677's enrollment target sits among peer trials

190 6th of 11 higher than 6 of 11 other Muscular Dystrophy trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Muscular Dystrophy trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT03257033 · 190 participants · Phase 3

    Intra-arterial Gemcitabine vs. IV Gemcitabine and Nab-Paclitaxel Following Radiotherapy for LAPC

  • NCT03642028 · 190 participants · Phase 4

    Suvorexant: A Dual Orexin Receptor Antagonist for Treating Sleep Disturbance in Posttraumatic Stress

  • NCT04015609 · 190 participants · NA

    Psychotherapy Intervention for Latinos With Advanced Cancer

  • NCT04284397 · 190 participants · Early Phase 1

    Identification of Critical Thermal Environments for Aged Adults

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT00313677, the US trial registry maintained by the National Library of Medicine. NCT00313677 (mid enrollment · single site footprint · recruiting) retrieved and formatted by PlainTrial, see methodology.